wuhan
specif
antivir
drug
urgent
need
treat
infect
main
proteas
pro
key
cov
enzym
play
pivot
role
mediat
viral
replic
transcript
make
attract
drug
target
effort
rapidli
discov
lead
compound
target
pro
two
compound
design
synthes
exhibit
excel
inhibitori
activ
ic
valu
respect
significantli
compound
exhibit
potent
infect
activ
cellbas
assay
ec
valu
respect
xray
crystal
structur
pro
complex
determin
resolut
respect
crystal
structur
show
coval
inhibitor
aldehyd
group
bound
coval
pro
compound
show
good
pk
properti
vivo
also
exhibit
low
toxic
promis
drug
lead
clinic
potenti
merit
studi
sequenc
identifi
sarscov
novel
coronaviru
name
sever
acut
respiratori
syndrom
coronaviru
intern
committe
taxonomi
virus
pneumonia
design
world
health
organ
februari
coronavirus
envelop
positivesens
singlestrand
rna
virus
lack
abil
correct
error
occur
rna
replic
properti
result
high
variabl
cov
mutat
occur
frequent
quickli
environment
evolutionari
stress
therefor
rna
cov
highli
preval
sever
pathogen
viral
diseas
genom
rna
cov
approxim
k
nt
length
structur
tail
largest
viral
rna
genom
known
date
contain
least
open
read
frame
orf
frameshift
first
orf
twothird
genom
length
directli
translat
polyprotein
pp
polyprotein
process
proteas
pro
also
name
main
proteas
pro
one
two
papainlik
proteas
plp
nonstructur
protein
nsp
subsequ
nsp
catalyz
synthesi
nest
set
subgenom
rna
use
templat
directli
translat
main
structur
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
protein
includ
envelop
e
membran
spike
nucleocapsid
n
protein
therefor
proteas
especi
pro
play
vital
role
life
cycl
coronaviru
pro
pro
threedomain
domain
iii
cystein
proteas
involv
matur
cleavag
event
within
precursor
polyprotein
activ
pro
homodim
contain
two
protom
cov
pro
featur
noncanon
cy
dyad
locat
cleft
domain
ii
sever
common
featur
share
among
substrat
cov
pro
especi
gln
residu
almost
absolut
requir
substrat
posit
pro
conserv
within
group
cov
addit
human
homologu
pro
make
ideal
antivir
target
substrat
coronavirus
pro
pro
show
similar
proteas
inhibitor
peptidomimet
coval
inhibitor
deriv
natur
substrat
activ
site
highli
conserv
among
cov
pro
usual
compos
four
pocket
thiol
cystein
residu
pocket
anchor
inhibitor
coval
linkag
import
inhibitor
maintain
antivir
activ
design
new
inhibitor
aldehyd
select
new
warhead
occupi
ring
prove
suitabl
pocket
pro
pro
ring
expect
good
choic
new
inhibitor
furthermor
pocket
coronaviru
pro
usual
larg
enough
accommod
bigger
fragment
assess
possibl
stack
interact
hydrophob
interact
pocket
aryl
cyclohexyl
group
place
compound
final
indol
heterocyclic
group
privileg
skeleton
introduc
order
form
new
hydrogen
bond
improv
druglik
properti
synthet
procedur
synthet
rout
chemic
structur
compound
shown
scheme
start
materi
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
obtain
commerci
supplier
use
without
purif
synthes
key
intermedi
accord
literatur
intermedi
synthes
acid
tbutoxycarbonyl
group
remov
intermedi
obtain
coupl
compound
acid
yield
ester
peptidomimet
aldehyd
approach
via
twostep
rout
ester
deriv
first
reduc
nabh
gener
primari
alcohol
subsequ
oxid
aldehyd
dessmartin
periodinan
dmp
recombin
pro
pro
express
purifi
order
elucid
mechan
inhibit
pro
determin
highresolut
crystal
structur
complex
resolut
tabl
crystal
pro
belong
space
group
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
asymmetr
unit
contain
one
molecul
tabl
crystallograph
symmetri
axi
two
molecul
design
protom
protom
b
associ
homodim
figur
structur
protom
contain
three
domain
substratebind
site
locat
cleft
domain
ii
figur
activ
site
pro
cyshi
form
catalyt
dyad
figur
electron
densiti
map
clearli
show
compound
substrat
bind
pocket
pro
extend
conform
figur
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
enter
deep
site
stack
imidazol
ring
figur
cyclohexyl
group
also
surround
side
chain
produc
extens
hydrophob
interact
figur
indol
group
expos
solvent
site
stabil
hydrogen
bond
figur
side
chain
residu
interact
indol
group
hydrophob
interact
interestingli
multipl
water
molecul
name
play
import
role
bind
figur
interact
amid
bond
hydrogen
bond
wherea
form
number
hydrogen
bond
aldehyd
group
residu
contribut
stabil
bind
pocket
figur
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
cartoon
represent
crystal
structur
pro
complex
compound
shown
brown
stick
substratebind
pocket
locat
domain
ii
pro
water
molecul
involv
stabil
shown
sphere
color
red
b
closeup
view
bind
site
bind
pocket
divid
four
subsit
residu
involv
inhibitor
bind
shown
green
stick
water
molecul
shown
brown
stick
red
sphere
respect
hydrogen
bond
indic
dash
line
c
comparison
bind
model
pro
major
differ
mark
dash
circl
compound
shown
brown
green
stick
respect
closeup
view
bind
site
hydrogen
bond
indic
dash
line
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
crystal
structur
pro
complex
similar
complex
show
similar
inhibitor
bind
mode
figur
differ
bind
probabl
due
aryl
group
compar
cyclohexyl
group
aryl
group
undergo
signific
rotat
figur
side
chain
residu
interact
aryl
group
hydrophob
interact
figur
side
chain
stabil
aryl
group
addit
hydrogen
bond
figur
short
two
crystal
structur
reveal
ident
inhibitori
mechan
two
compound
occupi
substratebind
pocket
mimick
intermedi
catalyt
reaction
block
enzym
activ
pro
substanti
enzym
inhibit
result
evalu
abil
explor
druggabl
compound
two
compound
evalu
pharmacokinet
properti
shown
tabl
compound
given
intraperiton
intraven
display
long
halflif
h
high
maxim
concentr
c
max
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
ngml
good
bioavail
metabol
stabil
mice
also
good
cl
mlminmg
administ
intraperiton
subcutan
intraven
compound
also
show
good
pk
properti
consid
danger
select
intraven
drip
administr
studi
compar
administr
via
intraven
halflif
shorter
clearanc
rate
faster
cl
mlminmg
compound
select
investig
intraven
drip
dose
rat
dog
result
show
tabl
exhibit
long
rat
h
dog
low
clearanc
rate
rat
mlminkg
dog
mlminkg
high
auc
valu
rat
h
ngml
dog
h
ngml
result
indic
compound
good
pk
properti
warrant
studi
vivo
toxic
studi
tabl
carri
sd
rat
beagl
dog
acut
toxic
conduct
sd
rat
sd
rat
die
receiv
mgkg
via
intraven
drip
administr
dosag
rais
mgkg
one
four
sd
rat
die
dose
rang
toxic
studi
conduct
seven
day
dose
level
mgkg
sd
rat
mgkg
beagl
dog
daili
dose
qd
intraven
drip
anim
clinic
observ
day
least
obviou
toxic
observ
group
result
show
low
toxic
rat
dog
discuss
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
show
good
pk
properti
vivo
also
exhibit
low
toxic
promis
compound
head
clinic
studi
